Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/98401
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technologyen_US
dc.contributorSchool of Optometryen_US
dc.contributorResearch Centre for SHARP Visionen_US
dc.creatorTeo, AWJen_US
dc.creatorZhang, Jen_US
dc.creatorZhou, Len_US
dc.creatorLiu, YCen_US
dc.date.accessioned2023-04-27T01:05:49Z-
dc.date.available2023-04-27T01:05:49Z-
dc.identifier.urihttp://hdl.handle.net/10397/98401-
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).en_US
dc.rightsThe following publication Teo AWJ, Zhang J, Zhou L, Liu Y-C. Metabolomics in Corneal Diseases: A Narrative Review from Clinical Aspects. Metabolites. 2023; 13(3):380 is available at https://doi.org/10.3390/metabo13030380.en_US
dc.subjectCorneaen_US
dc.subjectCorneal diseasesen_US
dc.subjectMetabolomicsen_US
dc.titleMetabolomics in corneal diseases : a narrative review from clinical aspectsen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume13en_US
dc.identifier.issue3en_US
dc.identifier.doi10.3390/metabo13030380en_US
dcterms.abstractCorneal pathologies may have subtle manifestations in the initial stages, delaying diagnosis and timely treatment. This can lead to irreversible visual loss. Metabolomics is a rapidly developing field that allows the study of metabolites in a system, providing a complementary tool in the early diagnosis and management of corneal diseases. Early identification of biomarkers is key to prevent disease progression. The advancement of nuclear magnetic resonance and mass spectrometry allows the identification of new biomarkers in the analysis of tear, cornea, and aqueous humor. Novel perspectives on disease mechanisms are identified, which provide vital information for potential targeted therapies in the future. Current treatments are analyzed at a molecular level to offer further information regarding their efficacy. In this article, we provide a comprehensive review of the metabolomic studies undertaken in the cornea and various pathologies such as dry eye disease, Sjogren’s syndrome, keratoconus, post-refractive surgery, contact lens wearers, and diabetic corneas. Lastly, we discuss the exciting future that metabolomics plays in cornea research.en_US
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationMetabolites, Mar. 2023, v. 13, no. 3, 380en_US
dcterms.isPartOfMetabolitesen_US
dcterms.issued2023-03-
dc.identifier.scopus2-s2.0-85151515478-
dc.identifier.eissn2218-1989en_US
dc.identifier.artn380en_US
dc.description.validate202304 bcwwen_US
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumbera1992-
dc.identifier.SubFormID46246-
dc.description.fundingSourceSelf-fundeden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
metabolites-13-00380.pdf893.71 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

129
Last Week
0
Last month
Citations as of Nov 9, 2025

Downloads

49
Citations as of Nov 9, 2025

SCOPUSTM   
Citations

15
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

14
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.